Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie — Clinical Trial Site

60 Registered trials

34 Currently recruiting

Organisation

Szpital Kliniczny Ministerstwa Spraw Wewnetrznych I Administracji Z Warminsko-Mazurskim Centrum Onkologii W Olsztynie

Location

Olsztyn, Poland

Identifier

ORG-100043435

Address

Al. Wojska Polskiego 37, 10-228, Poland

Departments

#2301: Klinika Onkologii i Immunoonkologii z Oddziałem Dziennym Terapii Onkologicznej
Cardiology
Hematologii
Hematology Department
Klinika Ginekologii, Ginekologii Onkologicznej i Endokrynologii Ginekologicznej
KLINIKA ONKOLOGII I IMMUNO ONKOLOGI I ZODDZIA ŁEM DZIENNYM TERAPII ONKOLOGICZNEJ
Klinika Onkologii i Immunologii z Oddzialem Dziennym Terapii Onkologicznej
Klinika Onkologii i Immunologii z Oddziałem Dziennym Terapii Onkologicznej
Klinika Onkologii I Immunoonkologii
Klinika Onkologii i Immunoonkologii z Oddzialem Dziennym Terapii Onkologicznej
Klinika Onkologii i Immunoonkologii z Oddziałem Dziennym Terapii Onkologicznej
KLINIKA ONKOLOGII I IMMUNOONKOLOGII Z ODDZIAŁEM DZIENNYM TERAPII ONKOLOGICZNEJ
Klinika Onkologii i Immunoonkologii z Osrodkiem Dziennym Terapii Onkologicznej
Klinika Radioterapii
N/A
NA
Oddzal Kliniczny Hematologii i Chorob Wewnetrznych z Osrodkiem Transplantacji Szpiku
Oddzial Kliniczny Hematologii
Oddzial Kliniczny Hematologii i Chorob Wewnetrznych z Osrodkiem Transplantacji Szpiku
Oddzial Kliniczny Onkologii i Immunoonkologii z Osrodkiem Dziennym Terapii Onkologicznej
Oddział Hematologii
Oddział Hematologii i Transplantologii Szpiku
Oddział Kliniczny Hematologii
Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
Oddział Kliniczny Hematologii z ośrodkiem Transplantacji Szpiku
Oddział Kliniczny Onkologii i Immunoonkologii z Osrodkiem Dziennym Terapii Onkologicznej
Oddział Kliniczny Radioterapii
Oddział Radioterapii
Oncology
PL10051:Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku
POL003: Klinika Radioterapii
Urology and Urological Oncology

Clinical trials at this site (60)

Search interface

A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizu… Pending

2025-521587-35-00 Metastatic colorectal cancer 5
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which has Spread and Caused Significant Body Weight Lo… Recruiting

2025-522093-36-00 Cancer cachexia 10 2026-05-20
A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting

2025-524498-17-00 Pretreated Unresectable Locally Advanced or Metastatic 10 2026-05-08
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Rec… Recruiting

2025-520582-51-00 Hormone receptor positive breast cancer 5 2025-10-17
A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting

2024-519343-15-00 Low-grade Upper Tract Urothelial Cancer 5 2025-10-08
A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the… Recruiting

2024-518359-47-00 Acute Myeloid Leukemia 10 2025-06-17
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Acute myeloid leukemia 5 2025-05-05
A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemal… Recruiting

2023-507097-41-01 Patients with limited-stage small cell lung cancer (LS- 5 2025-03-20
A Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus BSC versus Placebo plus BSC in Participants with IPS… Recruiting

2022-500479-29-00 International Prognostic Scoring System-Revised (IPSS-R 10 2023-03-28
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting

2022-501374-19-00 Aggressive and Indolent B-cell Malignancies (mantle cel 4 2022-09-16
A Phase Ib/II Study of APG-2575 as a Single Agent or in Combination with Other Therapeutic Agents in Patients with Relapsed and/or Refractor… Recruiting

2024-515654-25-00 Relapsed and/or Refractory Chronic Lymphocytic Leukemia 9 2021-12-20
A trial to learn how safe the combination of rilvegostomig and chemotherapy is and how well it works compared to durvalumab and chemotherapy… Recruiting

2025-523085-24-00 Biliary Tract Cancer 5 2026-04-13
Phase III Study of Rilvegostomig in Combination withBevacizumab with or without Tremelimumab as First-lineTreatment of Hepatocellular Carcin… Recruiting

2024-518210-81-00 Advanced Hepatocellular Carcinoma 5 2026-03-18
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Chronic lymphocytic leukemia (CLL) 5 2025-12-16
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 9 2025-10-15
An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting

2024-520156-22-00 Metastatic hormone-sensitive prostate cancer 4 2025-10-08
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A study to evaluate the efficacy of APG-2575 (Lisaftoclax) plus azacitidine (AZA) vs. placebo plus AZA in newly diagnosed adult subjects wit… Recruiting

2024-517247-31-00 Newly Diagnosed Higher Risk Myelodysplastic Syndrome 5 2025-07-07
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 myelodysplastic neoplasms/syndromes (MDS) 5 2025-04-30
A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting

2024-515566-13-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2025-03-19
Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With Recurrent KRAS/NRAS and BRAF Wild-type Colorectal Cancer Recruiting

2024-513853-66-00 KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or 5 2025-02-04
Amivantamab + Chemotherapy Versus Cetuximab + Chemotherapy in Treatment-naïve Participants with KRAS/NRAS and BRAF Wild-type Colorectal Canc… Recruiting

2024-513852-13-00 KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic 5 2025-01-20